Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PADI1 | Q9ULC6 | 1/20 | 0.38 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2922056 | 0.98 | CHRM5 (0.55) | CHRM5CHRM3SIGMAR1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL4219766 | 0.96 | CHRM5 (0.53) | CHRM5CHRM3SIGMAR1MEN1KMT2A | |
| SCHEMBL6887723 | 0.96 | CHRM5 (0.53) | CHRM5CHRM3SIGMAR1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL8483418 | 0.96 | CHRM5 (0.53) | CHRM5CHRM3SIGMAR1MEN1KMT2A | |
| SCHEMBL2915702 | 0.91 | CHRM5 (0.53) | CHRM5CHRM3SIGMAR1MEN1KMT2A | |
| SCHEMBL16749995 | 0.86 | SIGMAR1 (0.49) | CHRM5CHRM3SIGMAR1MEN1KMT2A | |
| SCHEMBL31216071 | 0.84 | SIGMAR1 (0.43) | CHRM5CHRM3SIGMAR1MEN1KMT2A | |
| SCHEMBL1133592 | 0.83 | — | — | |
| SCHEMBL12379861 | 0.83 | TSHR (0.46) | TSHRHSD17B10SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL70778 | 0.83 | TSHR (0.46) | TSHRHSD17B10SMN1; SMN2ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635464-B2 | Selective targeting of apoptotic cells | NEW SOUTH INNOVATIONS PTY LIMITED (AU) | 2009-12-22 | — | — | US | disclosed |
| US-7635464-B2 | Selective targeting of apoptotic cells | NEW SOUTH INNOVATIONS PTY LIMITED (AU) | 2009-12-22 | — | — | US | disclosed |
| US-20090311179-A1 | Selective Targeting of Apoptotic Cells | NEW SOUTH INNOVATIONS PTY LIMITED (AU) | 2009-12-17 | — | — | US | disclosed |
| US-20090311179-A1 | Selective Targeting of Apoptotic Cells | NEW SOUTH INNOVATIONS PTY LIMITED (AU) | 2009-12-17 | — | — | US | disclosed |
| US-6180113-B1 | USED IN TUMOR THERAPY AND INTERVENTIONAL RADIOLOGY | SCHERING AG (DE) | 2001-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090311179-A1 | Selective Targeting of Apoptotic Cells | BAX, BAD, BCL2 | CHRM5 4850/4885CHRM3 4830/4885SIGMAR1 2935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.